Cavendish sees Poolbeg MHRA clearance as key de-risking event with 313% upside to target

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) shares rose as much as 8% on Wednesday after receipt of Clinical Trial Authorisation from the UK medicines regulator for its POLB 001 TOPICAL study. Cavendish said the milestone represents a key de-risking event and clears the final hurdle ahead of patient screening.